BGM Group Ltd. - Class A (BGM) closed at $8.20 on October 22, 2026, down 0.5% from the previous close, on volume of 39,606 shares (30-day average 40,460).
Data as of October 22, 2026.
No headlines found.
No press releases found.
No news found.
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
BGM Group Ltd. - Class A trades on the NASDAQ stock market under the symbol BGM.
As of October 22, 2026, BGM stock price declined to $8.20 with 39,606 million shares trading.
BGM has a beta of 2.64, meaning it tends to be more sensitive to market movements. BGM has a correlation of 0.05 to the broad based SPY ETF.
BGM has a market cap of $109.50 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that BGM belongs to (by Net Assets): ONEQ.
BGM has underperformed the market in the last year with a price return of -97.1% while the SPY ETF gained +14.9%. BGM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -8.9% and -12.7%, respectively, while the SPY returned +2.3% and -1.7%, respectively.
BGM support price is $7.29 and resistance is $9.19 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BGM shares will trade within this expected range on the day.
